Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Commercial Officer | January 10, 2025 | April 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date January 10, 2025 · Filed April 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 900,682 |
Reported balance
After 2025-01-10 transaction · row 1
1 source rowRow 1 · 2025-01-10 · Exercise / conversion · Acquired 958 · Balance 900,682 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2025-01-12 | Direct | 0 |
Reported balance
After 2025-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-10 · Exercise / conversion · Disposed 958 · Balance 0 F1: 100% of the shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 133,630 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · derivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,630 Underlying: Class A Common Stock · 133,630 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 11,768 | $3.84 | $45,189.12 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,355 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,330 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,123 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 234,375 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,793 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 11,887 | $3.84 | $45,646.08 |
DisclosureSEC source: 0002064832-26-000090 · form4a.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,724 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,818 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000090 · form4a.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,611 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 11,144 | $3.73 | $41,567.12 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,418 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 10,559 | $3.73 | $39,385.07 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,562 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 18,910 | $3.73 | $70,534.30 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,121 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,346 | $3.73 | $12,480.58 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,031 Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,060 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · derivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,060 shares Expires 2025-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,173 | $4.62 | $10,028.40 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,377 Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 4,060 | $2.47 | $10,028.20 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:52 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 189,369 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003228 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,369 Underlying: Class A Common Stock · 189,369 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:52 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 183,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003228 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,490 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 656 | $3.70 | $2,427.20 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,423 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,748 | $3.70 | $10,167.60 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,079 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 19,423 | $3.70 | $71,865.10 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,827 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 10,559 | $3.70 | $39,068.30 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,250 Read SEC document |
| January 10, 2025 Filed Apr 25, 2026 01:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 958 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0002064832-26-000183 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 958 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 10, 2025 Filed Apr 25, 2026 01:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 958 | $1.24 | $1,187.92 |
DisclosureSEC source: 0002064832-26-000183 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,977 | $2.80 | $5,535.60 |
DisclosureSEC source: 0001062993-24-007934 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,809 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 313,636 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004313 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,636 Underlying: Class A Common Stock · 313,636 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 173,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004313 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,786 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 799 | $3.48 | $2,780.52 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,317 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,346 | $3.68 | $12,313.28 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,116 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 18,738 | $3.68 | $68,955.84 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,462 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:21 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,408 | $2.13 | $5,129.04 |
DisclosureSEC source: 0001062993-23-008508 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,200 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 345,470 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004890 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,470 Underlying: Class A Common Stock · 345,470 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 291,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004890 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,608 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 799 | $2.75 | $2,197.25 |
DisclosureSEC source: 0001062993-23-004057 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,599 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,346 | $2.92 | $9,770.32 |
DisclosureSEC source: 0001062993-23-004057 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,398 Read SEC document |
| August 20, 2022 Filed Aug 24, 2022 21:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 805 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001062993-22-018718 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 805 shares Expires 2022-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 20, 2022 Filed Aug 24, 2022 21:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 805 | $1.46 | $1,175.30 |
DisclosureSEC source: 0001062993-22-018718 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:22 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,977 | $7.89 | $15,598.53 |
DisclosureSEC source: 0001062993-22-009817 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,939 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 799 | $7.78 | $6,216.22 |
DisclosureSEC source: 0001062993-22-004802 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,916 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 107,063 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004802 · form4.xml · derivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,063 Underlying: Class A Common Stock · 107,063 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 45,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004802 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,715 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,977 | $19.83 | $39,203.91 |
DisclosureSEC source: 0000899243-21-014962 · doc4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,572 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 82,556 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000031 · edgar.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,556 Underlying: Class A Common Stock · 82,556 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 10,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000031 · edgar.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,549 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:39 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 213,995 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000012 · edgar.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,995 Underlying: Class A Common Stock · 213,995 shares Expires 2030-04-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:39 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 32,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000012 · edgar.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,767 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,150 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001661181-20-000004 · edgar.xml · derivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Class A Common Stock · 1,150 shares Expires 2020-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 1,150 | $1.70 | $1,955.00 |
DisclosureSEC source: 0001661181-20-000004 · edgar.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Apr 16, 2020 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 667 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001661181-20-000004 · edgar.xml · derivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 667 shares Expires 2019-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 01, 2019 Filed Apr 16, 2020 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 667 | $1.70 | $1,133.90 |
DisclosureSEC source: 0001661181-20-000004 · edgar.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 60,900 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 11 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,900 Underlying: Common Stock · 60,900 shares Expires 2027-05-04 F16 · price: Received in connection with the Merger in exchange for an option to acquire 30,000 shares of common stock of Organogenesis for $7.01 per share. F15 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 102,200 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 10 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,200 Underlying: Common Stock · 102,200 shares Expires 2027-05-04 F14 · price: Received in connection with the Merger in exchange for an option to acquire 50,345 shares of common stock of Organogenesis for $7.01 per share. F13 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 30,450 | Not disclosed Strike: $1.18 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 9 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 Underlying: Common Stock · 30,450 shares Expires 2024-04-10 F12 · price: Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.38 per share. F11 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on April 1, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.